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Massachusetts.BACKGROUND A dilemma arises about the merits of conservative
management vs lead replacement and/or extraction when patients
with a Medtronic Sprint Fidelis lead undergo generator replace-
ment. Conﬂicting reports suggest that the fracture rate may
increase after generator change.
OBJECTIVE The purpose of this study was to investigate the effect
of generator replacement on Fidelis lead performance.
METHODS The Carelink PLUS cohort is composed of 21,500 Fidelis
leads (model 6949) implanted in 1,006 centers. The survival rate for
leads that remained active after the ﬁrst generator replacement was
compared with that for a control group with matched lead implant
duration, patient age, patient sex, and generator type using the
Kaplan-Meier method. The control group’s starting point was adjusted
to match the implant duration of each lead in the replacement group
to allow for the comparison of similarly aged leads.
RESULTS Of the 2,988 implanted leads in each group, there was
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1547-5271/$-see front matter B 2016 Heart Rhythm Society. All rights reserved.cases and controls (replacement, n ¼ 227; no replacement,
n ¼ 257; Fisher exact, P ¼ .169). Lead survival analysis dem-
onstrated that lead performance since the ﬁrst replace-
ment procedure did not differ from that of the matched control
group.
CONCLUSION The Fidelis lead survival rate after generator
replacement does not differ from that of the Fidelis leads that
have not had replacement. In the event of generator replace-
ment with no manifestation of lead fracture, the lead model,
patient age and life expectancy, ejection fraction, comorbid-
ities, ease of extraction, local extraction expertise, and patient
preference should be considered to determine the best course
of action.
KEYWORDS Implantable deﬁbrillator; Generator replacement; Lead
fracture; Lead extraction
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The Medtronic Sprint Fidelis lead family (Minneapolis, MN) is
composed of small diameter ventricular leads used to deliver
deﬁbrillation therapies to patients at risk for sudden cardiac
death. The Fidelis leads were withdrawn from the market in
October 2007 because of higher-than-expected fracture rates.
As lead extraction carries a certain level of risk, a dilemma
arises about the merits of conservative management ofremaining Fidelis leads in the ﬁeld vs implanting a new lead,
extracting a functioning lead, or both when patients undergo
generator replacement. The risk of a single procedure that
combines generator replacement with a lead intervention is
typically discussed when a system that includes an advisory
lead comes for generator replacement, weighed against the risk
of a second potential procedure in the event of a lead perform-
ance issue if simple generator replacement is preferred.
Conﬂicting reports1,2 suggest that the fracture rate may
increase after generator change. Small sample size, case
series studies from a limited number of implant centers
prompted the hypothesis that generator change may induce
strain on the lead that triggers an increase in fracture rate. We
tested this hypothesis in a large data set of patients under-
going remote monitoring, comparing potentially affected
patients to concurrent controls. The purpose of this study was
to investigate the effect of generator replacement on fracture-
free survival of the Fidelis lead in a large cohort, with the
potential to inform prophylactic lead replacement strategy at
the time of generator replacement.http://dx.doi.org/10.1016/j.hrthm.2016.05.001
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A retrospective analysis was performed on existing data
pulled from Medtronic’s Device and Registrant Tracking
and Global Complaint Handling databases. Data were also
reviewed from CareLink transmissions. A retrospective
cohort study was performed using the CareLink PLUS
population,3 comprising 21,500 model 6949 Fidelis leads
implanted in 1006 centers between August 2004 and
January 2006. The CareLink PLUS cohort is an existing
data set composed of a subset of registered patients in the
United States that were transmitting on the CareLink
network when the cohort was deﬁned in 2008. The purpose
of the cohort was to identify a group of patients to inform
leading edge performance and patient management recom-
mendations. Lead model 6949 is a dual coil, active ﬁxation
deﬁbrillation lead and was chosen for this study because of
its high volume relative to other Fidelis lead models. Every
6949 lead model that was implanted in the United States
before January 31, 2006, and had an available CareLink ﬁle
transmission between April 20, 2007, and April 15, 2008,
was included in the cohort. CareLink PLUS is a perform-
ance analysis that includes data from CareLink transmis-
sions plus returned product and save-to-disk analysis. The
median follow-up time in the CareLink PLUS study
population is 90.7 months.
Given the data sources used (existing data sets rather than
newly created sets through a traditional clinical trial setting),
no consent was necessary, as this activity did not result in
altered protocols or treatment for any patient. Patients
provided consent to undergo remote monitoring as part of
routine clinical care. Although serial numbers were included
in the data set for the purpose of determining patient
parameters for the analysis (ie, age, sex, and associated
devices), all patient identiﬁcation information was removed
from the aggregated data shown in the article.
Fractures were determined using several data sources.
CareLink transmissions from devices attached to cohort
leads were analyzed by trained Medtronic personnel for
indications of fractures. Fractures in the pacing circuit were
determined if 2 or more of the following criteria were met:
doubling of pacing impedance, a daily average of greater
than 8 short RR intervals (o200 ms), nonsustained tachy-
cardias under 220 ms, and noise on the electrogram.
Fractures in the high-voltage circuit were deﬁned by dou-
bling of high-voltage impedance and impedance greater than
100 Ω. Set screw issues and impedance spikes due to
disconnecting the lead from the device at change out were
excluded from the fracture criteria. In addition, the Med-
tronic complaint-handling database was used for information
on returned leads with conﬁrmed fractures, save-to-disk ﬁles
from returned implantable cardioverter-deﬁbrillators/cardiac
resynchronization therapy with deﬁbrillators (ICDs/CRT-
Ds), and other evidence of fracture such as x-ray ﬁlms.
Together, these data sources comprise the numerator of
fractured leads. The denominator or total population was
determined using Medtronic registry data for implant inter-
vals for each patient in the CareLink PLUS cohort. Deceasedpatients and non–fracture-related lead removals/replace-
ments were censored.
The CareLink PLUS cohort was broken into 2 smaller
groups on the basis of whether the lead had experienced
generator replacement during the follow-up period. There
were 8,900 Fidelis leads that remained active after generator
replacement. These leads were matched with a control
Fidelis lead with matched patient age, patient sex, and
generator type that had not undergone generator replacement
(n¼ 2,988 per group). Lead implant time was adjusted for by
shifting the starting point for the control leads to match the
duration between implant and ﬁrst generator replacement of
the corresponding lead in the replacement group. The
breakdown of the Carelink PLUS cohort into 2 subgroups
is displayed in Figure 1. The demographic characteristics of
the Carelink PLUS cohort and its 2 subgroups are summar-
ized in Table 1.
The fracture-free survival rates of the replacement and
control groups were compared using a Fisher exact test and a
Kaplan-Meier survival curve. The Kaplan-Meier curve was
generated on the basis of survival after the ﬁrst generator
replacement for the replacement group and survival after the
adjusted starting point for the control group to allow for the
comparison of similarly aged leads.
Burri and Combescure1 developed a decision model to
assess the long-term effect of different Fidelis lead manage-
ment strategies at generator replacement. The authors of the
decision model1 shared their R statistical software analysis
code to allow us to input the current large-scale fracture rate
estimate into the identical model. In brief, the model was
updated on the basis of the present analysis estimate of
fracture rates using 2 approaches. In the ﬁrst approach, the
fracture rate in years 1 and 6 from the present study was used
instead of the 20.8% value reported by Lovelock et al,2 and
the model’s baseline fracture rate of 7.2% in other years was
left unchanged.4 The second approach updated this baseline
fracture rate to a value of 3.0% on the basis of the CareLink
PLUS cohort. We compared the results of these 2 approaches
with those of the previously published model’s main analysis
as well as the sensitivity analysis at both 5 and 10 years.Results
The study involved a total of 5,976 replacement patients and
matched controls from a cohort of 21,500 CareLink Plus
patients (Table 1). The replacement group had 227 fracture
events (7.6%) after generator replacement, while the control
group had 257 fracture events (8.6%). There was no differ-
ence in survival probability between the replacement group
and the control group after matching patient age, patient sex,
device type, and implant time (Fisher exact, P ¼ .17).
Figure 2 compares the lead survival curve since the ﬁrst
change-out procedure with that for the matched control
group. As previously described, the control group’s starting
point is adjusted to match the implant duration of each lead
in the replacement group. The replacement and control
groups perform similarly. The Fidelis lead survival rate after
CareLink® PLUS Cohort
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Leads with No Generator 
Changeouts During Follow-up 
Period
n=12,405
Leads with Generator
Changeout During Follow-Up 
Period
n=8,900
Matched Leads with 
Changeout
n=2,988
Matched Leads with 
No Changeout
n=2,988
Unmatched
n=9,417
Unmatched
n=5,912
Matching based on Implant Duraon, Paent Age (±1 year), Paent Sex, and Device Type
Lead Failure Events
n=257
Lead Failure Events
n=227
Eligible CareLink® PLUS Cohort
n=21,305
Missing Demographic 
informaon
n=195
Figure 1 Breakdown of the Carelink PLUS cohort into replacement and control groups.
Heart Rhythm, Vol 13, No 8, August 20161620generator replacement from this cohort is higher than
previously reported rates as shown in Figure 2 with 95%
conﬁdence intervals.
In the sensitivity analysis that stems from the Burri and
Combescure analysis,1 the estimated risk of mortality,
reintervention, major complications, and inappropriate
shocks at 5 years after generator replacement (Figure 3;
10-year data in Online Supplemental Material 1) was
calculated using 3 strategies: generator replacement only,
generator and lead replacement, or lead extraction with
generator and lead replacement. These data imply that
retaining the lead exposes the patient to the expected ambient
Fidelis fracture rate with attendant inappropriate shocks and
reintervention risk, but in so doing defers the major
complication risk associated with lead extraction and simpleTable 1 Baseline demographic characteristics of CareLink PLUS cohort
Characteristic
CareLink PLUS cohor
(N ¼ 21,500)
Time to ﬁrst change out (replacement group) or
adjusted starting point (control group)
NA
Patient age (y) 65.6 ± 12.5
Patient sex: male (%) 75.5
Generator type: SC, DC, CRT (%) 21.1, 34.9, 43.2
Total lead implant time (mo) 90.7 (95% CI 89.3–
CRT ¼ cardiac resynchronization therapy; DC ¼ dual chamber (device); NA ¼lead replacement. The rate of reintervention and inappro-
priate shocks remained elevated because the model’s alter-
nate leads (standard pacing lead fracture rate estimated at
0.0%; Medtronic Sprint Quattro lead fracture rate 0.4%/y)
have lower fracture rates.Discussion
The present study strongly supports the conclusion that the
Fidelis lead survival rate after generator replacement does
not differ from the survival rate of the Fidelis leads that have
not had generator replacement. The survival rate for the
replacement group was actually higher than that for the
matched control group according to Kaplan-Meier analysis,
though not statistically signiﬁcant. However, it is difﬁcult tot Replacement group
(n ¼ 2988)
No replacement group
(n ¼ 2988)
65.2 ± 23.9 65.2 ± 23.9
65.1 ± 12.3 65.1 ± 12.3
74.9 74.9
15.0, 39.5, 45.6 15.0, 39.5, 45.6
92.3) 110.1 (95% CI 109.7–110.5) 88.9 (95% CI 87.7–90.2)
not applicable; SC ¼ single chamber (device).
Figure 2 Kaplan-Meier survival curve of leads that have undergone generator replacement (dashed line, n ¼ 2988) compared to that of similarly aged leads
that have not undergone generator replacement (solid line, n ¼ 2988).
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would be protective of the lead. Patients in the replacement
group required generator replacement before their matched
patients in the control group, and the resulting replacement
did not have an adverse effect on the functional Fidelis lead.
The leads were matched to reduce bias between the
replacement and control groups. The survival rate of the 6949
lead model CareLink PLUS cohort is lower for longer implant
durations, younger patients, patients with a single-chamber
device, and female patients, as illustrated in the ﬁgures in
Online Supplementary Material 2. A number of single and
multicenter studies have also reported female sex4,5 and
younger patients6–8 as predictors of higher lead failure hazard.
The reason for the higher risk for female patients is currently
unknown. It has been proposed that differences in vascular
anatomy between women and men may play a role.8 Patients
who are more active may be at higher risk for fracture due to
higher mechanical stresses to the lead than do more sedentary
patients, and generator type and age may be surrogates for
patient activity. For example, young patients are likely to be
relatively more active than older patients and patients with a
CRT device are likely to be less active than those with a single-
chamber ICD. It should be noted that conﬂicting reports in the
literature suggest patients with a CRT device (vs ICD) have a
neutral or higher risk of lead fracture.8,9
Lovelock et al2 reported a signiﬁcant increase (Po .001)
in the rate of lead fracture for leads that underwent a routinegenerator replacement (n ¼ 72 [20.8%]) as compared with
age-matched leads without generator replacement (n ¼ 150
[2.54%]) (see Online Supplemental Material 3). Burri and
Combescure1 later generated a decision model for Fidelis
leads at generator replacement using the reported 20.8%
fracture as an input for the expected fracture rate at the ﬁrst
and sixth year. The model concluded that lead revision
“should be seriously considered to avoid reintervention for
subsequent lead fracture and to reduce inappropriate shocks.”
In contrast, Roy et al10 reported a relatively lower fracture rate
of 6.5% for Fidelis leads after generator replacement, which is
consistent with the present large-scale report.
The results of this study differ from those of previously
published studies. The survival rate for Fidelis leads 1 year
after generator replacement reported here (96.5%) is consid-
erably higher than that reported in the Lovelock study
(79.2%).2 The published decision model used the 79.2%
year 1 survival rate as an input after generator replacement.1
There were some differences between the study presented
here and the Lovelock study.2 The Lovelock study is a small
single-center study that matched the study group (n ¼ 72)
and the control group (n ¼ 150) by lead age only. This study
presents a large multicenter study that matches the study
group (n ¼ 2,988) and the control group (n ¼ 2,988) by lead
age, patient age, patient sex, and device type. In addition, this
study determined fractures from multiple sources and
censored deceased patients instead of excluding them.11
Main Sensivity Updated 
Year 1
Updated all 
years
Fracture 
rate at year 
1
20.8%
(Lovelock, 
et al)
7.2%
(Birnie, et 
al)
3.2%
(Year 1 of 
this study)
3.2%
(Year 1 of 
this study)
Fracture 
rate years 
2-5
7.2%
(Birnie, et 
al)
7.2%
(Birnie, et 
al)
7.2%
(Birnie, et 
al)
3.0%
(CareLink
Cohort 
data)
A C
DB
Figure 3 Cumulative risks of inappropriate shocks (A), reinterventions (B), and life-threatening complications (C) at 5 years after generator replacement
calculated on the basis of the Burri and Combescure decision model1 using the fracture rate inputs provided in (D). All other decision model inputs were kept
consistent with the study of Burri and Combescure. ICD ¼ implantable cardioverter-deﬁbrillator.
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patient when facing generator replacement when an intact
Fidelis lead is present. Previous studies and guidelines5,12,13
have concluded that patient- and device/lead-speciﬁc char-
acteristics must be weighed in discussion with patients and
their values and preferences. The present study does not
support that the lead has a change in ongoing risk as a result
of the generator replacement procedure, so the only grounds
to contemplate a change in lead management is the oppor-
tunistic nature of opening the pocket. As time passes, the
potential risk of extracting this lead may increase as ﬁbrosis
increases, since the majority of these leads are now in the
order of 10 years old. Thus by this point, many clinicians will
not replace or extract an intact lead unless patient longevity
and preference suggest a reasonable probability of eventual
fracture and tolerance of the short-term incremental risk
of a more complex procedure (lead addition or extraction/
replacement).
This study was retrospective and therefore is subject to the
typical limitations of a retrospective analysis, such as the
potential for selection or information bias. The present
analysis may be limited by possible differences in patientactivity between the replacement and control groups. As
mentioned previously, generator type and age may be an
indication of patient activity. However, matching for these
parameters may not fully account for patient activity and
ejection fraction, which may be additional factors that
promote early fracture and were not controlled for in this
analysis.
The Carelink PLUS cohort is a small subset of the total
population of Fidelis leads implanted and therefore may not
be completely representative of the behavior of the lead in
general. However, the matching process used within this
analysis is a compelling argument that generator change has
no effect on the lead fracture rate. Furthermore, the analysis is
primarily directed to the detection of lead fracture, and lead
insulation breach is not speciﬁcally addressed, which may
variably contribute to lead durability after generator replacement.Conclusion
The Fidelis lead survival rate after replacement does not
differ from the survival rate of Fidelis leads that have not
had generator replacement. Immediately before generator
1623Krahn et al Lead Performance After ICD Generator Replacementchange, all lead management options should be discussed
with patients, and the updated decision model should help
inform this. The lead subtype, patient age, patient life
expectancy, ejection fraction, comorbidities, ease of extrac-
tion, and patient preference should be considered to deter-
mine the best course of action.
Appendix
Supplementary data
Supplementary data are available in the online version of this
article at http://dx.doi.org/10.1016/j.hrthm.2016.05.001.
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